Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2017-11-21 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
拟转让启迪古汉集团湖南医药有限公司股权评估项目资产评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an "资产评估报告" (Asset Evaluation Report) and is issued by an asset evaluation company. It details the evaluation of equity value for a subsidiary company, including extensive financial data, valuation methods (asset-based and income approaches), legal and regulatory references, and a comprehensive assessment of assets and liabilities as of a specific valuation date (July 31, 2017). The document is lengthy (15,000 characters) and contains detailed substantive financial and valuation information, not merely an announcement or summary. It is not an annual or interim financial report, nor a regulatory filing or announcement. It is a standalone audit/valuation report related to asset appraisal for a specific transaction (equity transfer). Therefore, it fits best under the category of Audit Report / Information (AR).
2017-11-21 Chinese
第八届监事会临时会议决议公告
Regulatory Filings Classification · 95% confidence The document is a short announcement of resolutions passed at a temporary supervisory board meeting of the company. It includes voting results on specific proposals but does not contain financial statements, detailed management discussion, or other comprehensive report content. The length is only 467 characters, indicating it is a brief announcement rather than a full report. It is not an AGM information document since it is a supervisory board meeting, not an annual general meeting. It is not a management change announcement or financial report. The document fits best as a Regulatory Filing (RNS) because it is a formal disclosure of board resolutions without detailed financial or operational data.
2017-11-21 Chinese
启迪古汉集团湖南医药有限公司审计报告
Interim / Quarterly Report Classification · 95% confidence The document is a detailed financial report for the period from February 23, 2016, to July 31, 2017, for 启迪古汉集团湖南医药有限公司. It includes extensive notes on accounting policies, financial statement preparation basis, accounting estimates, and detailed financial data such as cash, receivables, inventory, fixed assets, intangible assets, tax information, and more. The length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The content is consistent with a financial report covering a period shorter than a full fiscal year (about 7 months), which fits the definition of an Interim / Quarterly Report (IR). There is no indication that this is an announcement or certification only, nor is it a full annual report (10-K). Therefore, the classification is Interim / Quarterly Report (IR). H2 2017
2017-11-21 Chinese
第八届董事会临时会议独立董事意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion statement regarding specific board meeting decisions, including termination of a project and approval of a share transfer proposal. It references compliance with regulatory guidelines and company governance rules. The content is focused on board-level decisions and independent director opinions rather than full financial data or report publication. The document length is short (630 characters), and it is not a full report but a formal opinion related to board matters. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2017-11-21 Chinese
关于公开挂牌转让控股子公司古汉医药部分股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company about the public listing for transfer of part of the equity of its controlling subsidiary. It includes details about the transaction overview, approval by the board, conditions of the transaction, basic information about the subsidiary, equity structure, asset valuation report, financial data, and risk warnings. The document is not a full financial report but a detailed announcement of a capital transaction involving share transfer. It does not contain comprehensive financial statements or quarterly/yearly financial results but focuses on a capital/financing update related to the sale of subsidiary shares. The document length is 4432 characters, which is substantial and contains detailed transaction information, not just a brief notice or a report publication announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2017-11-21 Chinese
第八届董事会临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a company's board of directors meeting, specifically the eighth board meeting. It details decisions on project termination, capital increase changes, equity transfer, and credit facility application. The document includes voting results and authorization details but does not contain financial statements or detailed financial analysis. It is not an annual or interim report, earnings release, or audit report. It is not a regulatory filing or certification. The content fits the category of Board/Management Information, as it announces changes and decisions made by the board of directors.
2017-11-21 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.